CN109952383B - 用于预测恩扎妥林活性的方法和组合物 - Google Patents

用于预测恩扎妥林活性的方法和组合物 Download PDF

Info

Publication number
CN109952383B
CN109952383B CN201780066737.5A CN201780066737A CN109952383B CN 109952383 B CN109952383 B CN 109952383B CN 201780066737 A CN201780066737 A CN 201780066737A CN 109952383 B CN109952383 B CN 109952383B
Authority
CN
China
Prior art keywords
treatment
snp
snps
individual
enzastaurin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780066737.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109952383A (zh
Inventor
罗文�
孙红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suoyuan Biomedical Usa Co ltd
Original Assignee
Suoyuan Biomedicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suoyuan Biomedicine Co ltd filed Critical Suoyuan Biomedicine Co ltd
Publication of CN109952383A publication Critical patent/CN109952383A/zh
Application granted granted Critical
Publication of CN109952383B publication Critical patent/CN109952383B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780066737.5A 2016-09-01 2017-08-31 用于预测恩扎妥林活性的方法和组合物 Active CN109952383B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US62/382,734 2016-09-01
US201662414601P 2016-10-28 2016-10-28
US62/414,601 2016-10-28
PCT/US2017/049747 WO2018045240A1 (en) 2016-09-01 2017-08-31 Methods and composition for the prediction of the activity of enzastaurin

Publications (2)

Publication Number Publication Date
CN109952383A CN109952383A (zh) 2019-06-28
CN109952383B true CN109952383B (zh) 2024-01-05

Family

ID=59923555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780066737.5A Active CN109952383B (zh) 2016-09-01 2017-08-31 用于预测恩扎妥林活性的方法和组合物

Country Status (15)

Country Link
US (2) US11421280B2 (enExample)
EP (1) EP3507384B1 (enExample)
JP (3) JP7197915B2 (enExample)
KR (1) KR20190046935A (enExample)
CN (1) CN109952383B (enExample)
AU (1) AU2017318669B2 (enExample)
BR (1) BR112019003951A2 (enExample)
CA (1) CA3035386A1 (enExample)
JO (1) JOP20190025A1 (enExample)
MX (1) MX2019002377A (enExample)
PH (1) PH12019500422A1 (enExample)
RU (1) RU2019109011A (enExample)
SG (2) SG11201901762WA (enExample)
TW (2) TW202313973A (enExample)
WO (1) WO2018045240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
US20220193062A1 (en) * 2018-09-12 2022-06-23 Denovo Biopharma Llc Combination of enzastaurin and inhibitors of btk and uses thereof
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
TWI808838B (zh) * 2021-07-23 2023-07-11 高雄醫學大學 二代荷爾蒙藥物於治療攝護腺癌療效評估之臨床治療藥物預測暨推薦系統及方法
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
WO2012106267A1 (en) * 2011-01-31 2012-08-09 Wen Luo Method for discovering pharmacogenomic biomarkers
CN103649386A (zh) * 2011-06-08 2014-03-19 索元生物医药（杭州）有限公司 预测类视黄醇x受体调节剂活性的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014500A2 (en) * 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
WO2012106267A1 (en) * 2011-01-31 2012-08-09 Wen Luo Method for discovering pharmacogenomic biomarkers
JP2014506459A (ja) * 2011-01-31 2014-03-17 デノボ バイオマーカーズ インコーポレイテッド 薬理ゲノミクスバイオマーカーを発見するための方法
CN103649386A (zh) * 2011-06-08 2014-03-19 索元生物医药（杭州）有限公司 预测类视黄醇x受体调节剂活性的方法和组合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
An eQTL analysis of the human glioblastoma multiforme genome;Max Shpak et al;《Genomics》;20140304;第103卷(第4期);第252-263页 *
dbSNP.rs309604,chr:115118080(GRCh38.p13).《dbSNP》.2008,第1-10页. *
dbSNP.rs309605,chr:115117115(GRCh38.p13).《dbSNP》.2008,第1-10页. *
Efficacy of the Multi-Kinase Inhibitor Enzastaurin is Dependent on Cellular Signaling Context;Wen-Liang Kuo et al;《Mol Cancer Ther》;20100928;第9卷(第10期);第2814-2824页 *
Genetic polymorphisms in the DNA repair gene,XRCC1 associate with non-Hodgkin lymphoma susceptibility:A systematic review and meta-anaysis;Yuying Li et al;《European Journal of Medical Genetics》;20151223;第59卷(第2期);第91-103页 *
rs309604,chr:115118080(GRCh38.p13);dbSNP;《dbSNP》;20080526;第1-10页 *
rs309605,chr:115117115(GRCh38.p13);dbSNP;《dbSNP》;20080524;第1-10页 *
药物基因组学在肿瘤化疗中的应用与研究进展;熊萱等;《中国药房》;20150520;第26卷(第14期);第1-6页 *

Also Published As

Publication number Publication date
PH12019500422A1 (en) 2019-05-27
RU2019109011A3 (enExample) 2021-01-22
AU2017318669A1 (en) 2019-03-07
MX2019002377A (es) 2019-09-05
CN109952383A (zh) 2019-06-28
JP7197915B2 (ja) 2022-12-28
BR112019003951A2 (pt) 2019-06-25
US11421280B2 (en) 2022-08-23
TW202313973A (zh) 2023-04-01
SG11201901762WA (en) 2019-03-28
US20230074781A1 (en) 2023-03-09
TWI771317B (zh) 2022-07-21
US20190233902A1 (en) 2019-08-01
TW201812125A (zh) 2018-04-01
JP2022173308A (ja) 2022-11-18
EP3507384B1 (en) 2023-08-30
JP2019528705A (ja) 2019-10-17
RU2019109011A (ru) 2020-10-05
SG10201912134TA (en) 2020-02-27
KR20190046935A (ko) 2019-05-07
AU2017318669B2 (en) 2023-04-20
CA3035386A1 (en) 2018-03-08
WO2018045240A1 (en) 2018-03-08
EP3507384A1 (en) 2019-07-10
JP2020188816A (ja) 2020-11-26
JOP20190025A1 (ar) 2019-02-19

Similar Documents

Publication Publication Date Title
CN109952383B (zh) 用于预测恩扎妥林活性的方法和组合物
JP6440658B2 (ja) 薬理ゲノミクスバイオマーカーを発見するための方法
US10954563B2 (en) Method for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment
JP2023515665A (ja) 神経伝達物質トランスポーターの阻害剤の有効性を評価するための組成物及び方法
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: California, USA

Patentee after: Suoyuan biomedical (USA) Co.,Ltd.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: Suoyuan Biomedicine Co.,Ltd.

Country or region before: U.S.A.